dBET23 is a highly effective and selective PROTAC BRD4 degrader with a DC 50/5h of ~ 50 nM for BRD4 BD1 protein. In Vitro dBET23 occupies the canonical binding sites on CRBN and BRD4 BD1 for thalidomide and JQ1, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid